Health
Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus – News-Medical.Net
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory…
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.
The experimental mAbs, REGN3048 and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus to attach to and infect target cells. The mAbs were discovered and developed by scientists at the biopharmaceutical…
-
Business21 hours agoBrokers name 3 quality ASX 200 shares to buy today
-
Noosa News17 hours agoFirst home buyers’ options to almost double under expanded Home Guarantee Scheme
-
General23 hours agoExplosions heard in Qatar capital Doha, Israel announces strike on Hamas ‘senior leadership’
-
Noosa News18 hours agoSun Spirit sculpture returns ahead of Swell Sculpture Festival